Sexual dimorphism in metabolic dysfunction-associated steatotic liver disease (MASLD): An interaction and non-linear analysis of the relationship between TyG-BMI and FIB-4
Main Article Content
Abstract
While Triglyceride-Glucose Body Mass Index (TyG-BMI) is a robust marker for insulin resistance in metabolic dysfunction-associated steatotic liver disease (MASLD), its sex-specific relationship with the Fibrosis-4 (FIB-4) index remains unclear. This cross-sectional study analyzed 222 adult MASLD patients (104 males, 118 females) using multivariable linear regression with an interaction term (TyG-BMI × Sex) and Restricted Cubic Splines (RCS) to assess non-linear trajectories between TyG-BMI and log-transformed FIB-4, adjusting for clinical confounders. Sex-stratified models revealed profound sexual dimorphism. In females, TyG-BMI demonstrated a paradoxical, significant negative association with FIB-4 (β = -0.0033, p = 0.007). Conversely, no significant association existed in males (p = 0.590). RCS analysis confirmed a declining FIB-4 trajectory at higher TyG-BMI percentiles in females, whereas the male trajectory remained flat. Conclusively, the TyG-BMI and FIB-4 relationship is strongly modulated by sex in MASLD. The paradoxical negative correlation in females highlights estrogen's potential protective role against fibrogenesis and the mathematical limitations of FIB-4 in younger, obese populations, necessitating sex-aware clinical approaches.
Article Details
Keywords
MASLD, TyG-BMI, FIB-4, sexual dimorphism, liver fibrosis
References
2. Purnomo HD, Adiwinata R, Permatadewi CO, et al. The global landscape of lean MASLD: insight from Asia and the West. Front Gastroenterol. 2025;4:1699508. doi:10.3389/fgstr.2025.1699508
3. Truong XT, Lee DH. Hepatic Insulin Resistance and Steatosis in MASLD: New Insights into Mechanisms and Clinical Implications. Diabetes Metab J. 2025;49(5):964-986. doi:10.4093/dmj.2025.0644
4. Shangguan Q, Liu Q, Yang R, et al. Predictive value of insulin resistance surrogates for the development of diabetes in individuals with baseline normoglycemia. Diabetol Metab Syndr. 2024;16(1):68. doi:10.1186/s13098-024-01307-x
5. Qian X, Wu W, Chen B, et al. Value of TyG-BMI in predicting NAFLD in individuals with type 2 diabetes mellitus. Front Endocrinol. 2024;15:1425024. doi:10.3389/fendo.2024.1425024
6. Afonso-Alí A, Dicroce-Giacobini J, Teixido-Trujillo S, et al. Role of obesity and estrogen deficiency in non-alcoholic fatty liver disease: Insights from a mouse model. Mol Med Rep. 2025;31(3):264. doi:10.3892/mmr.2025.13629
7. Joo SK, Kim W. Sex differences in metabolic dysfunction-associated steatotic liver disease: a narrative review. Ewha Med J. 2024;47(2):e17. doi:10.12771/emj.2024.e17
8. McPherson S, Armstrong MJ, Cobbold JF, et al. Quality standards for the management of NAFLD. Lancet Gastroenterol Hepatol. 2022;7(8):755-769. doi:10.1016/S2468-1253(22)00061-9
9. Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006-1019. doi:10.1136/gutjnl-2021-324243
10. Zou H, Xie J, Ma X, et al. The Value of TyG-Related Indices in Evaluating MASLD and Significant Liver Fibrosis. Can J Gastroenterol Hepatol. 2025;2025:5871321. doi:10.1155/cjgh/5871321
11. Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79(6):1542-1556. doi:10.1016/j.jhep.2023.06.003
12. Ying Y, Ji Y, Ju R, et al. Association between the triglyceride-glucose index and liver fibrosis in adults with MASLD: a cross-sectional study. BMC Gastroenterol. 2025;25:3. doi:10.1186/s12876-024-03579-z
13. Suri A, Engel A, Engstrom E, et al. Sex-Specific Cardiometabolic Profiles and Severity of Liver Fibrosis. JAMA Netw Open. 2026;9(3):e260863. doi:10.1001/jamanetworkopen.2026.0863